SynthesisFrontiers in medicine2026
Effect of antibiotic regimens for bloodstream infections caused by KPC-producing enterobacter: a network meta-analysis.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study aimed to assess the impact of different antibiotic regimens on bloodstream infections (BSIs) caused by Klebsiella pneumoniae producing Klebsiella pneumoniae carbapenemase (KPC). Methods: A thorough literature search was performed using Web of Science, Embase, PubMed, and the Cochrane Library, which yielded 16 studies on antibiotic regimens for KPC-Ent BSI for network meta-analysis (NMA). We calculated pooled overall mortality rates along with 95% confidence intervals (CIs) and utilized the surface under the cumulative ranking curves (SUCRA) to evaluate the efficacy of antibiotic regimens. Results: Nineteen studies involving 10 treatment regimens were included in the network meta-analysis. For overall mortality, meropenem monotherapy (MEM_Mono) ranked highest, with the greatest probability of being the best treatment (SUCRA 84.0%; PrBest 64.0%). In the subgroup analysis, amikacin monotherapy (AMG_Mono) showed the highest ranking for 28-day mortality (SUCRA 91.3%), whereas MEM_Mono remained the top-ranked regimen for 30-day mortality (SUCRA 83.2%). The consistency and sensitivity analyses supported the robustness of the findings. Conclusion: Overall, the evidence suggests that MEM_Mono may be the most favorable regimen for KPC-Ent BSI, while the optimal treatment may vary according to the mortality assessment timepoint.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.